The effect of prophylactic probiotic lactobacilli in enteral feeding on nosocomiial pneumonia rates in critically ill patients.
- Conditions
- osocomial pneumonia rates in critically ill patients.Nosocomial pneumonia rates in critically ill patients.Respiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12605000543684
- Lead Sponsor
- Intensive Care, Royal Melbourne Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
1.Adult patient admitted to the ICU with an expected stay of more than 48 h.2.Patients who are to be commenced on enteral feeding via gastric or post-pyloric routes.3.Patients who consent or if the patient is incompetent, the next-of-kin who consent, to inclusion in the study.
1.Patients aged less than 18 years.2.Patients who are already receiving probiotic treatment.3.The Lactobacillus acidophilus preparation to be used in this study contains a very small amount of MSG (total dose 20 mg/day, equivalent to 10% of the initial dose used to test for MSG sensitivity) and as a precaution, patients with asthma or recurrent urticaria will be excluded.4.Patients with a known sensitivity to MSG will be excluded.5.Patients with HIV infection, pre-existing immunosuppression, or who are pregnant. As the Lactobacillus preparation contains live micro-organisms, immunosuppressed and pregnant patients will be excluded.6.Patients with a contra-indication to enteral feeding.7.Patients with a contra-indication to placement of an enteral feeding tube.8.Patients or next-of-kin who do not consent to inclusion in the study.9.Patients who are already enrolled in another study that may influence the outcome of the probiotic study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method